Levacetylleucine for the treatment of neurological manifestations of Niemann-Pick disease type C

INTRODUCTION: Niemann-Pick disease type C (NPC) is a rare, progressive, neurodegenerative lysosomal disorder for which disease-specific treatment options remain limited. Until recently, the standard of care drug miglustat was the only approved therapy that slows disease progression but there is a substantial unmet need for additional well-tolerated, orally available, central nervous system penetrant therapies. AREAS COVERED: This evaluation reviews the chemistry, pharmacology, pharmacokinetics, clinical efficacy, safety, and regulatory status of levacetylleucine, an oral modified amino acid approved in 2024-2026 for the neurological manifestations of NPC. Evidence is drawn from Phase 2, rater-blinded trial (IB1001-201), the pivotal, Phase 3 (IB1001-301), randomized, placebo-controlled crossover trial, and its long-term open-label Extension Phase. A structured search of PubMed, ClinicalTrials.gov, and regulatory databases through July 2026 was undertaken. EXPERT OPINION: Levacetylleucine produces a rapid, symptomatic benefit within 6-12 weeks and exhibits disease-modifying effects over ≥ 36 months, with an oral route of administration, and a benign safety profile. These attributes distinguish it from existing therapies and position it as a foundational treatment for NPC.